(Q35808438)

10 August 2017

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations (English)

1 reference

10 August 2017

14

Razelle Kurzrock

1 reference

10 August 2017

Ignacio Garrido-Laguna

10

object named as

Ignacio Garrido-Laguna

1 reference

Apostolia Maria Tsimberidou

10 August 2017

6

object named as

Apostolia M Tsimberidou

1 reference

10 August 2017

5

Aung Naing

1 reference

10 August 2017

1

Filip Janku

1 reference

10 August 2017

3

Shannon N Westin

1 reference

10 August 2017

13

Karen H Lu

1 reference

10 August 2017

Jennifer J Wheler

2

1 reference

10 August 2017

Stacy L Moulder

4

1 reference

10 August 2017

Siqing Fu

7

1 reference

10 August 2017

Gerald S Falchook

8

1 reference

10 August 2017

David S Hong

9

1 reference

10 August 2017

Rajyalakshmi Luthra

11

1 reference

10 August 2017

J Jack Lee

12

1 reference

10 August 2017

language of work or name

English

0 references

publication date

23 January 2012

1 reference

Journal of Clinical Oncology

10 August 2017

1 reference

10 August 2017

30

1 reference

10 August 2017

777-782

1 reference

10 August 2017

8

1 reference

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

High frequency of mutations of the PIK3CA gene in human cancers

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Mutations of the BRAF gene in human cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295566

Risks and benefits of phase 1 oncology trials, revisited

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22271473

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22271473

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2011.36.1196

1 reference

10 August 2017

1 reference

10 August 2017

1 reference